Horizon Kinetics Medical ETF MEDX
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.85%
- Net assets
- $19.1M
- Holdings
- 33
- 12-month distribution yield
- 1.12%
- Asset class
- Equity
Horizon Kinetics Medical ETF (MEDX) is an exchange-traded fund listed on the Nasdaq in the United States. Its category is Equity · Global (equity). Its last price was US$36.64 on 20 Oct 2026. Its expense ratio is 0.85% a year, from its prospectus dated 30 Apr 2026. It reported net assets of US$19.08 million as of 30 Jun 2026. Its latest holdings report lists 33 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$0.41 a unit, a 12-month distribution yield of 1.12%, paid yearly.
Fees
- Total annual operating expenses (gross)
- 0.85%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.85%
- Prospectus date
- 30 Apr 2026
- Filed with the SEC
- 27 Apr 2026
Size and reporting
- Net assets
- $19,076,938
- Total assets
- $19,458,220
- Holdings as of
- 30 Jun 2026
- Report made public
- 26 Aug 2026 (57 days after the month end)
Top holdings
Largest 25 of 33 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly & Co | US5324571083 | 18.46% | $3.5M | Equity (common) | United States | USD |
| 2 | US BANK MMDA - USBGFS 7 | No identifier reported | 9.19% | $1.8M | Short-term investment vehicles (cash funds) | United States | USD |
| 3 | AbbVie Inc | US00287Y1091 | 8.85% | $1.7M | Equity (common) | United States | USD |
| 4 | Novartis AG | US66987V1098 | 6.89% | $1.3M | Equity (common) | Switzerland | USD |
| 5 | Johnson & Johnson | US4781601046 | 5.59% | $1.1M | Equity (common) | United States | USD |
| 6 | Alkermes PLC | IE00B56GVS15 | 5.53% | $1.1M | Equity (common) | Ireland | USD |
| 7 | AstraZeneca PLC | GB0009895292 | 4.98% | $951K | Equity (common) | United Kingdom | USD |
| 8 | Ionis Pharmaceuticals Inc | US4622221004 | 4.53% | $865K | Equity (common) | United States | USD |
| 9 | Bristol-Myers Squibb Co | US1101221083 | 4.42% | $844K | Equity (common) | United States | USD |
| 10 | Merck & Co Inc | US58933Y1055 | 3.96% | $755K | Equity (common) | United States | USD |
| 11 | Amgen Inc | US0311621009 | 3.91% | $747K | Equity (common) | United States | USD |
| 12 | Alnylam Pharmaceuticals Inc | US02043Q1076 | 3.42% | $653K | Equity (common) | United States | USD |
| 13 | Biogen Inc | US09062X1037 | 3.09% | $589K | Equity (common) | United States | USD |
| 14 | Pfizer Inc | US7170811035 | 2.86% | $545K | Equity (common) | United States | USD |
| 15 | GSK PLC | US37733W2044 | 2.71% | $516K | Equity (common) | United Kingdom | USD |
| 16 | CRISPR Therapeutics AG | CH0334081137 | 2.64% | $503K | Equity (common) | Switzerland | USD |
| 17 | Regeneron Pharmaceuticals Inc | US75886F1075 | 2.06% | $393K | Equity (common) | United States | USD |
| 18 | Beam Therapeutics Inc | US07373V1052 | 1.51% | $288K | Equity (common) | United States | USD |
| 19 | Galectin Therapeutics Inc | US3632252025 | 1.14% | $218K | Equity (common) | United States | USD |
| 20 | Intellia Therapeutics Inc | US45826J1051 | 1.12% | $213K | Equity (common) | United States | USD |
| 21 | Sandoz Group AG | US7999261008 | 0.80% | $152K | Equity (common) | Switzerland | USD |
| 22 | Replimune Group Inc | US76029N1063 | 0.73% | $139K | Equity (common) | United States | USD |
| 23 | Vanda Pharmaceuticals Inc | US9216591084 | 0.73% | $139K | Equity (common) | United States | USD |
| 24 | Haleon PLC | US4055521003 | 0.60% | $115K | Equity (common) | United Kingdom | USD |
| 25 | Lantern Pharma Inc | US51654W1018 | 0.55% | $105K | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 92.64% | |
| Short-term investment vehicles (cash funds) | 9.19% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 77.40% | |
| Switzerland | 10.33% | |
| United Kingdom | 8.57% | |
| Ireland | 5.53% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 101.83% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 71.29% | |
| Consumer Discretionary | 0.60% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $0.4090
- 12-month yield
- 1.12%
- Frequency
- Yearly
- Latest ex-date
- 23 Dec 2025
12-month yield = distributions per unit with an ex-date in the last 12 months ($0.4090) ÷ latest price ($36.64) × 100 = 1.12%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (3 payments)
| Ex-date | Amount per unit |
|---|---|
| 23 Dec 2025 | $0.4090 |
| 24 Dec 2024 | $0.5020 |
| 27 Dec 2023 | $1.6420 |
Filings and sources
- Form N-PORT report for June 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000078972) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- MEDX and VT Vanguard Total World Stock Index ETF
- MEDX and SMH VanEck Semiconductor ETF
- MEDX and SOXX iShares PHLX SOX Semiconductor Sector Index Fund
- MEDX and CGDV Capital Group Dividend Value ETF